阿德福韦酯与拉米夫定治疗慢性乙型肝炎对比分析

Comparative Study of Adefovir Dipivoxil and Lamivudine in the Treatment of Chronic Hepatitis B

目的比较阿德福韦酯(贺维力)与拉米夫定(贺普丁)治疗慢性活动性乙型肝炎的临床疗效,以提高有效率,减少耐药性。方法收集我院2008年12月～2011年1月经消化内科应用上述两种药物系统治疗慢性活动性乙型肝炎患者150例,根据用药分为三组各50例:分别为使用贺维力、贺普丁及两种药物合用。分别于治疗的12、24、36、52周观察HBV-DNA病毒复制情况及ALT阴转率,比较各组间患者的临床疗效。结果贺维力组连续治疗52周,各时期HBV-DNA转阴率分别为32.0%、54.0%、62.0%、74.0%;贺普丁组分别为48.0%、52.0%、52.0%、66.0%;联合用药组分别为48.0%、54.0%、68.0%、78.0%。经过贺维力组连续治疗52周,各时期ALT转阴率分别为30.0%、44.0%、76.0%、70.0%;贺普丁组分别为60.0%、68.0%、80.0%、72.0%;联合用药组分别为62.0%、66.0%、74.0%、74.0%。结论治疗52周时,贺维力组HBV-DNA及ALT转阴率略好于贺普丁组,与联合用药组无明显差异。

Objective To compare the power of Adefovir dipivoxil and Lamivudine in the treatment of chronic active hepatitis B clinical efficacy,so as to improve efficiency. Methods All of 150 cases were collected which were treated by two drugs we mentioned in our hospital from Desember 2008 to Janury 2011. All cases in three groups according the treatment： group l：Adefovir Dipivoxil; group 2： Lamivudine ; Group 3： two drugs combination used, 50 cases respectively.in the treatment of 12 weeks, 24 weeks, 36 weeks, 52 weeks observed HBV-DNA viral replication and ALT negative rate, comparing the clinical efficacy between every two groups ,and analysis the result. Results After 52 weeks treatment, in group 1 the HBV-DNA negative rates were 32.0%, 54.0%, 62.0%, 74.0%; in group 2： 48.0%, 52.0%, 52.0%, 66.0%; in group 3： 48.0%, 54.0%, 68.0%, 78.0%. After continuous treatment by Adefovir Dipivoxil for 52 weeks, the ALT negative rates were,1：30.0%, 44.0%, 76.0%, 70.0%; group 2： 60.0%, 68.0%, 80.0%, 72.0%; group 3：62.0%, 66.0%, 74.0%, 74.0%. Conclusion After 52 weeks treatment by the drug of group 1,the negative ratio of HBV-DNA and ALT slightly better than group 2, with no significant difference in the group 3.